FDA Approves Enspryng (Satralizumab) as First Subcutaneous Treatment for Thyroid Eye Disease

The U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). This interleukin-6 receptor inhibitor is notable as the first subcutaneous therapy for the condition, allowing for at-home administration after patient training. The approval follows a priority review, adding a second indication for the drug, which was previously approved for neuromyelitis optica spectrum disorder.